目次

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3.Limitations

3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2.Breakdown of Primary Respondents
3.5. Forecasting Modality
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation

4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities

5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis

6. GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY TYPE
6.1. Overview
6.2. HSV-based Oncolytic Viruses
6.3. Adenoviruses-based Oncolytic Viruses
6.4. Others

7. GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION
7.1. Overview
7.2. Melanoma
7.3. Prostate Cancer
7.4. Breast Cancer
7.5. Ovarian Cancer
7.6. Lung Cancer
7.7. Others

8. GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY REGION
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America

9. COMPETITIVE LANDSCAPE
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Oncolytic Virotherapy Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Oncolytic Virotherapy Market,
9.7. Key developments and Growth Strategies
9.7.1. New Product Launch/Service Deployment
9.7.2. Merger & Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income, 2023
9.8.2. Major Players R&D Expenditure. 2023

10. COMPANY PROFILES
10.1. Lokon Pharma
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Amgen
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Transgene SA
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. VYRIAD
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Sorrento Therapeutics
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. ONCOLYS BIOPHARMA
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Targovax
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. CG ONCOLOGY INC.
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. TILT BIOTHERAPEUTICS
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. VCNBiosciences
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. DNAtrix
10.11.1. Company Overview
10.11.2. Financial Overview
10.11.3. Products Offered
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
10.12. Replimune Group Inc.
10.12.1. Company Overview
10.12.2. Financial Overview
10.12.3. Products Offered
10.12.4. Key Developments
10.12.5. SWOT Analysis
10.12.6. Key Strategies

11. APPENDIX
11.1. References
11.2. Related Reports

LIST OF TABLES
TABLE 1 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, SYNOPSIS, 2019-2032
TABLE 2 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)
TABLE 3 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 4 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 7 US: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 8 US: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 9 CANADA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 10 CANADA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 1 EUROPE: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 2 EUROPE: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 3 GERMANY: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 4 GERMANY: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 5 FRANCE: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 6 FRANCE: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 7 ITALY: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 8 ITALY: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 9 SPAIN: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 10 SPAIN: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 11 UK: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 12 UK: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 17 JAPAN: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 18 JAPAN: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 19 CHINA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 20 CHINA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 21 INDIA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 22 INDIA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 23 AUSTRALIA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 24 AUSTRALIA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 33 AFRICA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 34 AFRICA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: ONCOLYTIC VIROTHERAPY MARKET, BY TYPE, 2019-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: ONCOLYTIC VIROTHERAPY MARKET, BY APPLICATION, 2019-2032 (USD BILLION)

LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ONCOLYTIC VIROTHERAPY MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ONCOLYTIC VIROTHERAPY MARKET
FIGURE 4 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, SHARE (%), BY TYPE, 2023
FIGURE 5 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, SHARE (%), BY APPLICATION, 2023
FIGURE 6 GLOBAL ONCOLYTIC VIROTHERAPY MARKET, SHARE (%), BY REGION, 2023
FIGURE 7 NORTH AMERICA: ONCOLYTIC VIROTHERAPY MARKET, SHARE (%), BY REGION, 2023
FIGURE 8 EUROPE: ONCOLYTIC VIROTHERAPY MARKET, SHARE (%), BY REGION, 2023
FIGURE 9 ASIA-PACIFIC: ONCOLYTIC VIROTHERAPY MARKET, SHARE (%), BY REGION, 2023
FIGURE 10 REST OF THE WORLD: ONCOLYTIC VIROTHERAPY MARKET, SHARE (%), BY REGION, 2023
FIGURE 11 GLOBAL ONCOLYTIC VIROTHERAPY MARKET: COMPANY SHARE ANALYSIS, 2023 (%)
FIGURE 12 LOKON PHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 LOKON PHARMA: SWOT ANALYSIS
FIGURE 14 AMGEN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 AMGEN: SWOT ANALYSIS
FIGURE 16 VYRIAD: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 VYRIAD: SWOT ANALYSIS
FIGURE 18 TRANSGENE SA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 TRANSGENE SA: SWOT ANALYSIS
FIGURE 20 SORRENTO THERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 SORRENTO THERAPEUTICS: SWOT ANALYSIS
FIGURE 22 ONCOLYS BIOPHARMA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 ONCOLYS BIOPHARMA: SWOT ANALYSIS
FIGURE 24 TARGOVAX: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 TARGOVAX: SWOT ANALYSIS
FIGURE 26 CG ONCOLOGY INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 CG ONCOLOGY INC.: SWOT ANALYSIS
FIGURE 28 TILT BIOTHERAPEUTICS: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 TILT BIOTHERAPEUTICS: SWOT ANALYSIS
FIGURE 30 VCNBIOSCIENCES: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 VCNBIOSCIENCES: SWOT ANALYSIS
FIGURE 32 DNATRIX: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 33 DNATRIX: SWOT ANALYSIS
FIGURE 34 REPLIMUNE GROUP INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 35 REPLIMUNE GROUP INC.: SWOT ANALYSIS
Source: https://www.marketresearchfuture.com/reports/oncolytic-virotherapy-market/toc